A phase I‐II design based on periodic and continuous monitoring of disease status and the times to toxicity and death. (7th April 2020)

• Record Type: Journal Article
• Authors: Lee, Juhee; F. Thall, Peter; Msaouel, Pavlos
• Is Part Of: Statistics in medicine. Volume 39:Number 15(2020)
• Page Start: 2035
• Page End: 2050
• Publication Date: 2020-04-07
• Subjects: adaptive randomization -- Bayesian design -- dose finding -- interim response -- mixed hazard -- phase I‐II clinical trial; Medical statistics -- Periodicals; Statistique médicale -- Périodiques; Statistiques médicales -- Périodiques; 610.727
• DOI: 10.1002/sim.8528
• Languages: English
• ISSNs: 0277-6715

Abstract

Abstract : A Bayesian phase I‐II dose‐finding design is presented for a clinical trial with four coprimary outcomes that reflect the actual clinical observation process. During a prespecified fixed follow‐up period, the times to disease progression, toxicity, and death are monitored continuously, and an ordinal disease status variable, including progressive disease (PD) as one level, is evaluated repeatedly by scheduled imaging. We assume a proportional hazards model with piecewise constant baseline hazard for each continuous variable and a longitudinal multinomial probit model for the ordinal disease status process and include multivariate patient frailties to induce association among the outcomes. A finite partition of the nonfatal outcome combinations during the follow‐up period is constructed, and the utility of each set in the partition is elicited. Posterior mean utility is used to optimize each patient's dose, subject to a safety rule excluding doses with an unacceptably high rate of PD, severe toxicity, or death. A simulation study shows that, compared with the proposed design, a simpler design based on commonly used efficacy and toxicity outcomes obtained by combining the four variables described above performs poorly and has substantially smaller probabilities of correctly choosing truly optimal doses and excluding truly unsafe doses.